Case report: Successful treatment of anti‐MDA5‐positive to negative dermatomyositis‐associated interstitial lung disease with the JAK inhibitor tofacitinib
Abstract Objective Anti‐MDA5 antibody‐positive dermatomyositis (DM) is a rare clinical autoimmune disease, and anti‐MDA5‐positive DM with interstitial lung disease (ILD) is the most important cause of death in DM patients. We reported the efficacy of the JAK1/3 inhibitor tofacitinib as an anti‐MDA5‐...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-06-01
|
| Series: | Immunity, Inflammation and Disease |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/iid3.897 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850269449997778944 |
|---|---|
| author | Zong Jiang Xiaoling Yao Fang Tang Wukai Ma |
| author_facet | Zong Jiang Xiaoling Yao Fang Tang Wukai Ma |
| author_sort | Zong Jiang |
| collection | DOAJ |
| description | Abstract Objective Anti‐MDA5 antibody‐positive dermatomyositis (DM) is a rare clinical autoimmune disease, and anti‐MDA5‐positive DM with interstitial lung disease (ILD) is the most important cause of death in DM patients. We reported the efficacy of the JAK1/3 inhibitor tofacitinib as an anti‐MDA5‐negative treatment option for patients with anti‐MDA5‐positive DM‐ILD. Method and process Here we report a 51‐year‐old female patient with cough, sputum, shortness of breath for 5 months, rash for 3 months, and muscle pain in the extremities for 1 month. After conventional immunosuppressive therapy plus hormone therapy, the remission was slow. Methylprednisolone was successfully reduced after we administered tofacitinib and tacrolimus. After 132 weeks of follow‐up, anti‐MDA5 antibody turned negative, clinical symptoms were relieved, and lung Imaging tests were successfully reversed. Results and Conclusion There is currently no report of tofacitinib supplement therapy for anti‐MDA5 positive to negative DM. With this case report, tofacitinib is an option for the treatment of anti‐MDA5‐positive DM‐ILD, which deserves attention. |
| format | Article |
| id | doaj-art-55e0729645a843eead8fb4d082d1fcb6 |
| institution | OA Journals |
| issn | 2050-4527 |
| language | English |
| publishDate | 2023-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Immunity, Inflammation and Disease |
| spelling | doaj-art-55e0729645a843eead8fb4d082d1fcb62025-08-20T01:53:08ZengWileyImmunity, Inflammation and Disease2050-45272023-06-01116n/an/a10.1002/iid3.897Case report: Successful treatment of anti‐MDA5‐positive to negative dermatomyositis‐associated interstitial lung disease with the JAK inhibitor tofacitinibZong Jiang0Xiaoling Yao1Fang Tang2Wukai Ma3Second Clinical Medical College Guizhou University of Traditional Chinese Medicine guiyang ChinaSecond Clinical Medical College Guizhou University of Traditional Chinese Medicine guiyang ChinaDepartment of Internal Medicine The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine Guiyang ChinaDepartment of Internal Medicine The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine Guiyang ChinaAbstract Objective Anti‐MDA5 antibody‐positive dermatomyositis (DM) is a rare clinical autoimmune disease, and anti‐MDA5‐positive DM with interstitial lung disease (ILD) is the most important cause of death in DM patients. We reported the efficacy of the JAK1/3 inhibitor tofacitinib as an anti‐MDA5‐negative treatment option for patients with anti‐MDA5‐positive DM‐ILD. Method and process Here we report a 51‐year‐old female patient with cough, sputum, shortness of breath for 5 months, rash for 3 months, and muscle pain in the extremities for 1 month. After conventional immunosuppressive therapy plus hormone therapy, the remission was slow. Methylprednisolone was successfully reduced after we administered tofacitinib and tacrolimus. After 132 weeks of follow‐up, anti‐MDA5 antibody turned negative, clinical symptoms were relieved, and lung Imaging tests were successfully reversed. Results and Conclusion There is currently no report of tofacitinib supplement therapy for anti‐MDA5 positive to negative DM. With this case report, tofacitinib is an option for the treatment of anti‐MDA5‐positive DM‐ILD, which deserves attention.https://doi.org/10.1002/iid3.897Anti‐MDA5 antibodydermatomyositisinterstitial lung diseaseJAK inhibitortofacitinib |
| spellingShingle | Zong Jiang Xiaoling Yao Fang Tang Wukai Ma Case report: Successful treatment of anti‐MDA5‐positive to negative dermatomyositis‐associated interstitial lung disease with the JAK inhibitor tofacitinib Immunity, Inflammation and Disease Anti‐MDA5 antibody dermatomyositis interstitial lung disease JAK inhibitor tofacitinib |
| title | Case report: Successful treatment of anti‐MDA5‐positive to negative dermatomyositis‐associated interstitial lung disease with the JAK inhibitor tofacitinib |
| title_full | Case report: Successful treatment of anti‐MDA5‐positive to negative dermatomyositis‐associated interstitial lung disease with the JAK inhibitor tofacitinib |
| title_fullStr | Case report: Successful treatment of anti‐MDA5‐positive to negative dermatomyositis‐associated interstitial lung disease with the JAK inhibitor tofacitinib |
| title_full_unstemmed | Case report: Successful treatment of anti‐MDA5‐positive to negative dermatomyositis‐associated interstitial lung disease with the JAK inhibitor tofacitinib |
| title_short | Case report: Successful treatment of anti‐MDA5‐positive to negative dermatomyositis‐associated interstitial lung disease with the JAK inhibitor tofacitinib |
| title_sort | case report successful treatment of anti mda5 positive to negative dermatomyositis associated interstitial lung disease with the jak inhibitor tofacitinib |
| topic | Anti‐MDA5 antibody dermatomyositis interstitial lung disease JAK inhibitor tofacitinib |
| url | https://doi.org/10.1002/iid3.897 |
| work_keys_str_mv | AT zongjiang casereportsuccessfultreatmentofantimda5positivetonegativedermatomyositisassociatedinterstitiallungdiseasewiththejakinhibitortofacitinib AT xiaolingyao casereportsuccessfultreatmentofantimda5positivetonegativedermatomyositisassociatedinterstitiallungdiseasewiththejakinhibitortofacitinib AT fangtang casereportsuccessfultreatmentofantimda5positivetonegativedermatomyositisassociatedinterstitiallungdiseasewiththejakinhibitortofacitinib AT wukaima casereportsuccessfultreatmentofantimda5positivetonegativedermatomyositisassociatedinterstitiallungdiseasewiththejakinhibitortofacitinib |